The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis (uveitis)

December 9, 2015 updated by: Ozlem Sahin

Non-infectious and Infectious Uveitis Diagnosis

This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease. Sarcoidosis, ankylosing spondylitis and Behcet's disease are the most common autoimmune inflammatory diseases involving the eye.

Elevated serum angiotensin converting enzyme levels have also been reported in tuberculosis. Syphilis and tuberculosis are the most common infectious diseases involving the eye.

Study Type

Interventional

Enrollment (Anticipated)

280

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey
    • Ankara
      • Cankaya, Ankara, Turkey, 06450
        • Recruiting
        • DunyaGoz hospital Tunus caddesi no.28 kavaklidere
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 years to 86 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects have ocular inflammation diagnosed as sarcoidosis, ankylosing spondylitis, behcet's disease
  • Subjects have ocular infection diagnosed as tuberculosis and syphilis
  • Subjects have refractive errors only

Exclusion Criteria:

  • Subjects using ACE inhibitors, systemic steroids, immunosuppressive or immunomodulatory therapies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: serum angiotensin converting enzyme
spectrophotometric assay
Other: spectrophotometric assay
measurement of enzyme activity in the serum
Other: radial immunodiffusion
measurement of the precipitated ring diameters showing enzyme activity in the serum
Active Comparator: serum lysozyme
radial immunodiffusion
Other: spectrophotometric assay
measurement of enzyme activity in the serum
Other: radial immunodiffusion
measurement of the precipitated ring diameters showing enzyme activity in the serum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Analysis of serum angiotensin converting enzyme level
Time Frame: 1 day
1 day

Secondary Outcome Measures

Outcome Measure
Time Frame
Analysis of serum lysozyme level
Time Frame: 1 day
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ozlem Sahin

Investigators

  • Study Chair: Ioannis Pallikaris, MD, DunyaGoz Hospital, Etiler, yanarsu sokak no.1 besiktaş Istanbul Turkey

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Anticipated)

February 1, 2016

Study Completion (Anticipated)

January 1, 2017

Study Registration Dates

First Submitted

November 26, 2015

First Submitted That Met QC Criteria

December 9, 2015

First Posted (Estimate)

December 10, 2015

Study Record Updates

Last Update Posted (Estimate)

December 10, 2015

Last Update Submitted That Met QC Criteria

December 9, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DGH-070

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis

Clinical Trials on spectrophotometric assay

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe